Physician profile
Derek Crouthers
NPI 1962908343
$9,325.47
in general payments reported to CMS, 2019-2025
48 companies · $2,877 in 2025
The $2,877 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $1,439 · 2023: $1,927 · 2024: $2,742 · 2025: $2,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,546.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,705.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $986.79 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $905.48 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $663.42 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $600.15 | 2021-2025 | |
| Lilly USA, LLC | $586.46 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $569.06 | 2022-2025 | Otezla, Repatha, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $362.82 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.95 | 2022-2025 | Jardiance, Jascayd |
| Astellas Pharma US INC | $227.67 | 2023-2025 | Veozah |
| Abbott Laboratories | $217.69 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $217.33 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $207.84 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $147.92 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.52 | 2023-2025 | Trintellix |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $133.58 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $133.32 | 2023-2025 | Gvoke Hypopen |
| Insulet Corporation | $102.96 | 2025 | Omnipod |
| Exact Sciences Corporation | $101.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $100.81 | 2022-2023 | |
| Inspire Medical Systems, INC. | $94.87 | 2023-2025 | Inspire |
| Amarin Pharma, INC. | $88.35 | 2021-2022 | |
| Biogen, INC. | $80.05 | 2024-2025 | Skyclarys |
| Dexcom, INC. | $76.73 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.52 | 2024-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $54.15 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $52.12 | 2022-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $46.89 | 2021-2023 | Seglentis |
| Harmony Biosciences LLC | $37.20 | 2025 | |
| Almatica Pharma LLC | $33.89 | 2021-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $32.09 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $30.85 | 2023 | Quviviq |
| Tonix Medicines, INC. | $26.45 | 2025 | Tonmya |
| Supernus Pharmaceuticals, INC. | $24.48 | 2023 | Qelbree |
| Vertex Pharmaceuticals Incorporated | $20.43 | 2025 | |
| Kerecis Limited | $20.33 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Verona Pharma, INC. | $20.25 | 2025 | Ohtuvayre |
| Azurity Pharmaceuticals, INC. | $19.05 | 2023 | Edarbi |
| Nevro Corp. | $18.96 | 2023 | Senza |
| Paratek Pharmaceuticals, INC. | $18.19 | 2024 | Nuzyra |
| Medtronic, INC. | $17.99 | 2025 | Inceptiv |
| Biohaven Pharmaceutical Holding Company LTD. | $17.38 | 2022 | |
| Merck Sharp & Dohme LLC | $16.98 | 2023 | Belsomra |
| Esperion Therapeutics, INC. | $14.29 | 2024 | Nexletol |
| Boston Scientific Corporation | $14.15 | 2022 | |
| Antares Pharma, INC. | $13.97 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.94 | 2024 | Voquezna |
| Recordati_rare_diseases_inc. | $13.52 | 2025 | Isturisa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Crouthers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.